Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design
- PMID: 30946041
- DOI: 10.1097/COH.0000000000000548
Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design
Abstract
Purpose of review: It is believed that broadly neutralizing antibodies (bNAbs) will be an important component of an effective HIV-1 vaccine. Several immunogens have been designed that can target specific precursor B cells as a first step in a vaccine strategy to elicit bNAbs.
Recent findings: Germline-targeting immunogens have been developed that specifically engage precursors of reproducible classes of anti-HIV antibodies, such as VRC01-class and apex-directed bNAbs. However, these precursors represent only a small portion of the immune repertoire and any antigen will inherently present off-target epitopes to the immune system that may confound bNAb development. Novel animal models are being utilized to understand the competitive fitness of bNAb precursors in the context of immunization with germline-targeting immunogens. In parallel, immunogen design efforts are being pursued to favor the development of bNAb responses over off-target responses following immunization. New studies of bNAb precursor interactions with glycosylated Env variants can inform prime-boost regimens geared towards accelerating bNAb development.
Summary: Germline-targeting immunogens hold promise as a first step in eliciting a bNAb response through vaccination. A better understating of how efficiently germline-targeting immunogens can specifically target rare bNAb precursors is emerging. In addition, a more comprehensive structure-based understanding of critical barriers to bNAb elicitation, as well as commonalities between bNAb classes can further inform vaccine design.
Similar articles
-
Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies.J Int AIDS Soc. 2021 Nov;24 Suppl 7(Suppl 7):e25831. doi: 10.1002/jia2.25831. J Int AIDS Soc. 2021. PMID: 34806332 Free PMC article. Review.
-
HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen.Science. 2016 Mar 25;351(6280):1458-63. doi: 10.1126/science.aad9195. Science. 2016. PMID: 27013733 Free PMC article.
-
Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.Immunol Rev. 2017 Jan;275(1):89-107. doi: 10.1111/imr.12505. Immunol Rev. 2017. PMID: 28133799 Free PMC article. Review.
-
HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.Science. 2015 Jul 10;349(6244):156-61. doi: 10.1126/science.aac5894. Epub 2015 Jun 18. Science. 2015. PMID: 26089355 Free PMC article.
-
Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction.Cell Host Microbe. 2024 May 8;32(5):693-709.e7. doi: 10.1016/j.chom.2024.04.006. Epub 2024 Apr 25. Cell Host Microbe. 2024. PMID: 38670093
Cited by
-
Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.Vaccine. 2023 Oct 6;41(42):6309-6317. doi: 10.1016/j.vaccine.2023.07.046. Epub 2023 Sep 9. Vaccine. 2023. PMID: 37679276 Free PMC article. Clinical Trial.
-
SARS-CoV-2 spike-reactive naïve B cells and pre-existing memory B cells contribute to antibody responses in unexposed individuals after vaccination.Front Immunol. 2024 Feb 14;15:1355949. doi: 10.3389/fimmu.2024.1355949. eCollection 2024. Front Immunol. 2024. PMID: 38420128 Free PMC article.
-
Common evolutionary features of the envelope glycoprotein of HIV-1 in patients belonging to a transmission chain.Sci Rep. 2020 Oct 7;10(1):16744. doi: 10.1038/s41598-020-73975-4. Sci Rep. 2020. PMID: 33028961 Free PMC article.
-
Antibodies to combat viral infections: development strategies and progress.Nat Rev Drug Discov. 2022 Sep;21(9):676-696. doi: 10.1038/s41573-022-00495-3. Epub 2022 Jun 20. Nat Rev Drug Discov. 2022. PMID: 35725925 Free PMC article. Review.
-
Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?Cell Host Microbe. 2020 Apr 8;27(4):507-518. doi: 10.1016/j.chom.2020.03.018. Cell Host Microbe. 2020. PMID: 32272076 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous